Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.

Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS.

Future Oncol. 2018 Jul 12. doi: 10.2217/fon-2018-0178. [Epub ahead of print]

PMID:
30001151
2.

Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.

Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME.

Breast Cancer Res Treat. 2018 Jan;167(1):117-122. doi: 10.1007/s10549-017-4506-z. Epub 2017 Sep 18.

PMID:
28921303
3.

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply.

Melisko ME, Hwang J, Rugo HS.

JAMA Oncol. 2017 Aug 1;3(8):1142. doi: 10.1001/jamaoncol.2017.2077. No abstract available.

PMID:
28727874
4.

Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):161. doi: 10.1007/s10549-017-4350-1. No abstract available.

PMID:
28660429
5.

Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13. Erratum in: Breast Cancer Res Treat. 2017 Aug;165(1):161.

PMID:
28503722
6.

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.

Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, B├ągeman E, D'Agostino RB Jr, Ver Hoeve ES, Esserman L, Cigler T.

JAMA. 2017 Feb 14;317(6):606-614. doi: 10.1001/jama.2016.21038.

7.

A randomized pilot trial of a positive affect skill intervention (lessons in linking affect and coping) for women with metastatic breast cancer.

Cheung EO, Cohn MA, Dunn LB, Melisko ME, Morgan S, Penedo FJ, Salsman JM, Shumay DM, Moskowitz JT.

Psychooncology. 2017 Dec;26(12):2101-2108. doi: 10.1002/pon.4312. Epub 2016 Dec 27.

8.

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.

JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.

PMID:
27832260
9.

Quality of Posttreatment Care Among Breast Cancer Survivors in the University of California Athena Breast Health Network (Athena).

Ganz PA, Hahn EE, Petersen L, Melisko ME, Pierce JP, Von Friederichs-Fitzwater M, Lane KT, Hiatt RA.

Clin Breast Cancer. 2016 Oct;16(5):356-363. doi: 10.1016/j.clbc.2016.05.003. Epub 2016 May 14.

10.

Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications.

Melisko ME, Gradishar WJ, Moy B.

Am Soc Clin Oncol Educ Book. 2016;35:e22-9. doi: 10.14694/EDBK_159203. Review.

11.

Sexual Function in Cancer Survivors: Updates to the NCCN Guidelines for Survivorship.

Melisko ME, Narus JB.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):685-9.

PMID:
27226515
12.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
13.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

14.

Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.

Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW.

Breast Cancer Res Treat. 2015 Nov;154(2):339-49. doi: 10.1007/s10549-015-3610-1. Epub 2015 Oct 31.

PMID:
26520840
15.

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP.

Breast Cancer Res Treat. 2015 Aug;153(1):173-81. doi: 10.1007/s10549-015-3511-3. Epub 2015 Jul 25.

PMID:
26208485
16.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
17.

SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.

Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME.

Cancer. 2015 Mar 15;121(6):893-9. doi: 10.1002/cncr.29088. Epub 2014 Dec 2.

18.

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM.

J Clin Oncol. 2014 May 10;32(14):1472-9. doi: 10.1200/JCO.2013.52.1161. Epub 2014 Apr 7.

19.

Provider perceptions and expectations of breast cancer posttreatment care: a University of California Athena Breast Health Network project.

Hahn EE, Ganz PA, Melisko ME, Pierce JP, von Friederichs-Fitzwater M, Lane KT, Hiatt RA.

J Cancer Surviv. 2013 Sep;7(3):323-30. doi: 10.1007/s11764-013-0269-7. Epub 2013 Mar 15.

20.

Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer.

Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP.

Cancer. 2012 Mar 15;118(6):1710-7. doi: 10.1002/cncr.26459. Epub 2011 Sep 1.

21.

Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.

Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP.

Cancer. 2012 Apr 1;118(7):1933-9. doi: 10.1002/cncr.26403. Epub 2011 Aug 17.

22.

A changing perspective: improving access to fertility preservation.

Letourneau JM, Melisko ME, Cedars MI, Rosen MP.

Nat Rev Clin Oncol. 2011 Jan;8(1):56-60. doi: 10.1038/nrclinonc.2010.133. Epub 2010 Aug 24. Review.

23.

Amelioration of sexual adverse effects in the early breast cancer patient.

Melisko ME, Goldman M, Rugo HS.

J Cancer Surviv. 2010 Sep;4(3):247-55. doi: 10.1007/s11764-010-0130-1. Epub 2010 Jul 4. Review.

24.

Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.

Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN.

J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.

25.

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.

Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW.

Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.

26.

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.

Melisko ME, Glantz M, Rugo HS.

Nat Clin Pract Oncol. 2009 Jan;6(1):25-33. doi: 10.1038/ncponc1243. Epub 2008 Oct 21. Review.

PMID:
18936791
27.

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.

Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS.

J Neurooncol. 2008 Jul;88(3):359-65. doi: 10.1007/s11060-008-9578-5. Epub 2008 Apr 9.

PMID:
18398574
29.

Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers.

Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D.

Clin Breast Cancer. 2005 Apr;6(1):45-54.

PMID:
15899072
30.

Brain metastases of breast cancer.

Melisko ME, Kunwar S, Prados M, Berger MS, Park JW.

Expert Rev Anticancer Ther. 2005 Apr;5(2):253-68. Review.

PMID:
15877523
31.

Reactivation of hepatitis C virus after chemotherapy for colon cancer.

Melisko ME, Fox R, Venook A.

Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5.

PMID:
15191008

Supplemental Content

Loading ...
Support Center